41st Asia-Pacific Academy of Ophthalmology Congress (APAO 2026)
05 February - 08 March, 2026, Hong Kong
Low-concentration atropine reduced parapapillary gamma zone enlargement in a concentration-dependent manner over 3 years. Continuous treatment with 0.05 percent atropine demonstrated efficacy in controlling gamma zone development, according to latest findings from the LAMP Gamma zone study presented by study author Dr Jason Yam of the Chinese University of Hong Kong at APAO 2026.
Treatment naivety, lower baseline intraretinal fluid (IRF) and subretinal fluid (SRF) volume, lower baseline central subfield thickness (CST), greater IRF and SRF volume reduction, and greater CST reduction at week 16 in patients with diabetic macular oedema (DME) are predictive of longer treatment intervals with faricimab 6.0 mg at years 1 and 2, according to the results of the phase III YOSEMITE/RHINE trials.
